|
|
|
Rib-X Snares $22M
|
Business New Haven
2/18/2002
By: Lisa Micali
|
NEW HAVEN - Rib-X Pharmaceuticals Inc., a bioscience company focused on the discovery of new anti-infectives, announced that it has raised approximately $22 million in a Series A financing. The company will exploit a proprietary high-resolution crystal structure of the ribosome to discover new antibiotic agents. The ribosome performs the essential biological function of protein synthesis, and is the target for many known antibiotics. Rib-X has exclusively licensed the high-resolution ribosome structure that was discovered by two of the company's founders, Thomas Steitz and Peter Moore, both of Yale University.
|
Go FirstGo PreviousGo
NextGo LastGo
to Index
|
|
